Tumor Treating Fields (TTFields) are an effective treatment modality delivered via the continuous, noninvasive application of low-intensity (1-3 V/cm), alternating electric fields in the frequency range of several hundred kHz. The study of TTFields in tissue culture is carried out using the TTFields in vitro application system, which allows for the application of electric fields of varying frequencies and intensities to ceramic Petri dishes with a high dielectric constant (Ɛ > 5,000). Cancerous cell lines plated on coverslips at the bottom of the ceramic Petri dishes are subjected to TTFields delivered in two orthogonal directions at various frequencies to facilitate treatment outcome tests, such as cell counts and clonogenic assays. The results presented in this report demonstrate that the optimal frequency of the TTFields with respect to both cell counts and clonogenic assays is 200 kHz for both ovarian and glioma cells.
Introduction
Tumor Treating Fields (TTFields) are an anti-mitotic modality for the treatment of glioblastoma multiforme and potentially other cancer types. The fields are delivered via the continuous application of low-intensity (1-3 V/cm), intermediate-frequency (100-500 kHz), alternating electric fields to the region of the tumor 1, 2 . TTFields application in vitro and in vivo was shown to inhibit both the growth of various cancerous cell lines and the progression of the tumors in several animal tumor models 1, 2, 3, 4, 5, 6, 7 . Pilot clinical trials and larger randomized studies in patients with solid tumors, including glioblastoma and non-small cell lung cancer, have demonstrated the safety and efficacy of continuous TTFields application 8, 9, 10 . The efficacy of the TTFields was found to be: (1) frequency-dependent, with specific optimal frequencies leading to the highest reduction in the cell counts of cell lines from different origins 1, 2, 4, 5, 6, 7 ; (2) electric field intensity-dependent, with a minimal threshold for activity at around 1 V/cm and more potent higher intensities 1, 2, 7, 11 ; (3) enhanced when the treatment duration was longer 5 ; and (4) higher when 2 directional TTFields were applied perpendicularly to each other, as compared to electric fields applied from a single direction 1 . Based on the above findings, TTFields can be applied to patients for long durations using 2 sets of transducer arrays localized on the patients' skin to maximize the electric field intensities in the tumor bed 12, 13 .
Studying the effects of TTFields on cancerous cells in vitro currently provides the only way to determine the optimal frequency to apply to a specific tumor type. Testing for the optimal frequency requires a device that allows for the application of different frequencies in the range of 100-500 kHz and at intensities of up to 3 V/cm root mean square (RMS) to the cell culture. As TTFields application produces heat, the application system requires the ability to dissipate excessive heat while maintaining tight control over the temperature.
Several devices were developed throughout the years to allow for TTFields application to cell cultures 1, 2, 5, 14, 15, 16 . In all of these devices, the electrodes used were insulated in order to avoid the caveats involved with the use of conductive electrodes, such as electron exchange at the electrode surface and the release of toxic metal ions into the medium 1 . The main difference between the various TTFields application systems tested is the type of electrode insulation used, with either electrodes made of metal wires insulated with a thin film of insulator 2, 14, 15, 16 or with a high dielectric-constant material (e.g., lead magnesium niobate-lead titanate (PMN-PT)) 6 . While the insulated-wire electrodes offer a relatively simple and cost-effective solution for TTFields application, they are often limited by the high voltage required to achieve effective electric field intensities above the 1 V/cm threshold and by the surface available for cell plating, as the distance between the electrodes is relatively small. Systems based on electrodes insulated using a high dielectric-constant material require special design and manufacturing capabilities, yet they do not require high voltage and can offer a larger area for cell growth between the electrodes.
The TTFields in vitro application system used in this work belongs to the latter class of systems, with the core unit being a Petri dish (TTFields dish, see Figure 1 ) composed of high dielectric-constant ceramic (i.e., PMN-PT). Two pairs of electrodes are printed perpendicularly on the outer walls of a TTFields dish to allow for the application of electric fields from 2 directions. The electrodes are connected to a sinusoidal waveform generator and an amplifier, which allow for TTFields application in the frequency range of 50-500 kHz. In order to dissipate the excessive heat, the TTFields dishes are kept inside a refrigerated incubator, with the medium temperature-control performed using constant monitoring of the dish temperature and adjustments to the voltage applied by the system. In practice, setting the incubator to a lower temperature would lead to higher electric field intensities, as the system increases the voltage until the target temperature within the dish is achieved. The difference between the temperature within the dish and the incubator temperature may lead to some evaporation, depending on the temperature gradients; hence, the culture medium needs to be replaced every 24 h to maintain adequate growth conditions.
The protocol below describes the experimental procedure to optimize the application of TTFields frequencies to cancerous cells so that a maximum reduction in cell count and a reduction in the potential of the surviving cells to form colonies are achieved.
Protocol

TTFields In Vitro Application System -Base Plate and Dish Maintenance
1. Rinse dishes and dish covers under running tap water. Then rinse with deionized water and air-dry face down. 2. If a chemotherapeutic agent/drug has been added to dishes in a prior experiment, fill each dish with a 5% light detergent solution and leave overnight.
1. Rinse the dishes thoroughly under running tap water to avoid any traces of detergent inside the dish. Rinse the dishes and dish covers with deionized water and air-dry face down. 
Experiment Setup
NOTE: All equipment and materials used in this protocol are described in the Materials List. All steps below should be performed inside a laminar flow cabinet while sterile conditions are maintained.
1. Prepare clean and sterile TTFields dishes and covers, as described in section 1. Wipe the base plate with a cloth lightly moistened with 70% ethanol. 2. Install the TTFields dishes with the covers onto the base plate by pressing down gently on the dish and rotating clockwise by about 5 mm until the rim of the dish locks onto the three pins on the base plate. Place a sterile 22-mm coverslip (treated plastic or glass) on the bottom of each dish. 3. Prepare the cell suspension in complete growth medium (Dulbecco's modified Eagle's medium for U-87 MG and F98; RPMI for A2780 and OVCAR-3; supplemented as described in Materials List).
NOTE:
The cell concentrations depend on the cell types and experiment duration, 80%-90% confluent cell growth should not be exceeded by the end of the experiment. CAUTION: Human cell lines may represent a biological hazard and should be handled with the appropriate safety measures. 4. Place 200 µL of cell suspension (usually 5,000-20,000 cells in 200 µL for a 72-h experiment, depending on the doubling time) as a drop in the center of each coverslip and cover with the dish lids. 5. Incubate at 37 °C in a CO 2 incubator until the cells adhere; an overnight incubation is possible at this stage. 6. Aspirate the fluids from the drop using a 200-or 1,000-µL pipette. 7. Gently pipette 2 mL of complete growth medium to fill each dish. Use a sterile tip to pipette and softly tap on the coverslip edges to release the air bubbles occasionally caught under the slide. 8. Cover the dishes with their lids and place them inside a CO 2 incubator at 37 °C until the start of the TTFields treatment.
TTFields Application
1. Transfer the base plates with the attached TTFields dishes to a refrigerated CO 2 incubator.
NOTE: In vitro TTFields application will generate heat; therefore, a refrigerated incubator is required to compensate for the warming of the dishes. Higher TTFields intensities will produce more heat and will require lower incubator ambient temperatures (see Table 1 ). Clinically relevant TTFields intensities are achieved when the incubator temperature for TTFields application is in the range of 18-30 °C. 2. Connect the flat cable female connector to the base plate. Switch the TTFields generator on. 3. Start the TTFields in vitro application system software and select the experiment settings.
1. Define a new experiment. Type the name of the experiment and the experiment owner in the software user interface on the computer screen. Adjust the frequency and target temperature for each dish or base plate.
4. Start the TTFields application using the software. 5. Verify that all dishes are connected properly and appear light blue on the monitor. If a dish is circled with a red frame (meaning that it is not properly connected), press it down gently and rotate slowly back and forth until the contacts are restored and the dish appears light blue. 6. Leave the TTFields in vitro application system running for up to 24 h. 
Discussion
TTFields are an emerging anti-tumor modality based on the continuous application of properly tuned alternating electric fields 1, 2, 8, 9, 10, 17 . Maximizing anti-tumor efficacy is a desirable outcome for all treatment modalities. Thus, "fighting" for every additional percent of cancerous cell growth inhibition may have a significant effect on the long-term clinical outcome for patients. This is because of the required continuous nature of TTFields application and the resulting cumulative effect. Maximizing TTFields application can be achieved in several ways: (1) increasing the electric field intensity 1, 7 , (2) lengthening treatment duration 5 , (3) finding the most effective combination with other treatment modalities 18, 19 , and (4) defining the optimal frequency 1, 2, 4, 6, 7 . Maximizing the electric field intensity at the site of the tumor is achieved by optimizing the location of the arrays on the patient skin; this allows for the delivery of the maximal field intensity to the tumor based on the individual anatomy of the patient 20 . Lengthening treatment duration mostly relies on patient compliance with treatment (for at least 18 h per day) 17 . Finding the right combination with other therapies and determining the optimal frequency relies heavily on in vitro results, as no validated markers for TTFields treatment outcomes are currently available. In this work, we have outlined the experimental procedures required to determine the optimal TTFields frequency for cancerous cell lines using the TTFields in vitro application system. The methods described here can potentially be used to screen the combination of other cancer treatment modalities (e.g., chemotherapy agents or irradiation) with TTFields and to determine the optimal frequency for TTFields administration for each specific combined treatment.
In line with previous publications, the results shown here demonstrate that the optimal frequency for the treatment of both glioma cells and ovarian cancer cells is 200 kHz 1, 7 . In this work, we demonstrated for the first time that the optimal TTFields frequency to reduce the clonogenic potential is associated with the frequency that leads to the maximal cytotoxic effect. The methods used in this work to quantify the effects of TTFields (i.e., cytotoxic and clonogenic) are only two of many possible standard endpoint assays to evaluate treatment outcomes. Additional treatment outcome tests include: (1) fixing, staining, and mounting the coverslips on which the cells are plated over a microscope for the visualization of intracellular structures; (2) performing assays of protein and RNA extracts, either from the TTFields dishes themselves or after transferring the coverslip to a new disposable dish; and (3) trypsinizing cells stained for flow cytometry analysis.
Careful experimental planning will impact the treatment outcomes after the delivery of TTFields. The key steps include ensuring that the cell proliferation throughout the experiment does not lead to overgrowth and using the appropriate electric field intensity, as intensities that are too high when applied to sensitive cell lines will result in too-few cells for the required assays to determine the optimal frequency. Conversely, TTFields applied at very low intensities on less sensitive cell lines will result in small effects that may be masked by inherent variation. The treatment logs should be examined for valuable information regarding temperature stability, electrical currents, and resistance for each and every dish throughout the experiment. Replacing faulty dishes at treatment start and excluding data from a dish that did not meet the desirable treatment parameters will minimize variability between replicates.
In summary, TTFields are an emerging anticancer treatment modality that has already demonstrated efficacy and safety in clinical settings 8, 9, 10 . Testing TTFields in an in vitro setting using the protocols described here may allow for the optimization of TTFields treatment parameters in the clinical setting and may broaden our understanding of the underlying mechanism of action.
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